The Role of Personalized Medicine in Treating Complex Neurological Disorders

Peluso Polidura*

Department of Neurology, University of Turku, Turku University Hospital, 20520 Turku, Finland

Introduction

The field of medicine has evolved considerably over the past few decades, bringing about advancements that aim to tailor treatment strategies to the unique needs of individual patients. One of the most significant developments in this era of medical innovation is the rise of personalized medicine. Personalized medicine, sometimes referred to as precision medicine, is a medical model that utilizes an individual's genetic profile, lifestyle, environment, and other factors to guide the diagnosis, treatment, and prevention of diseases. This approach has shown immense promise across a wide range of medical conditions, from cancers to chronic diseases. However, one area where personalized medicine is gaining particularly notable attention is in the treatment of complex neurological disorders. Neurological disorders are a class of diseases that affect the brain, spinal cord, and peripheral nerves, with many of them being chronic, progressive, and difficult to treat. Disorders such as Parkinson's disease, Alzheimer's disease, multiple sclerosis, epilepsy, and amyotrophic lateral sclerosis (ALS) have long presented significant challenges for physicians. These disorders can vary widely in terms of their presentation, progression, and response to treatment, making it difficult to implement a one-size-fits-all approach [1].

Description

Complex neurological disorders are conditions that involve dysfunction in the nervous system, which is responsible for controlling and coordinating every action within the human body. The Central Nervous System (CNS), which consists of the brain and spinal cord, and the Peripheral Nervous System (PNS), which encompasses the network of nerves outside the CNS, can be affected by a variety of diseases and conditions. Some of these disorders are purely genetic, while others are influenced by environmental factors, lifestyle choices, and autoimmune responses. The complexities of these disorders arise from the heterogeneity in their causes, manifestations, and progression. A neurodegenerative disorder characterized by tremors, rigidity, bradykinesia (slowness of movement), and postural instability. PD is caused by the gradual loss of dopamine-producing neurons in the brain, leading to motor and cognitive dysfunction. The most common form of dementia, Alzheimer's disease leads to memory loss, confusion, changes in behavior, and eventually, loss of cognitive function. The underlying cause is the accumulation of amyloid plaques and tau tangles in the brain [2].

Personalized medicine holds great promise for the treatment of these complex neurological disorders. Traditional treatment approaches for neurological disorders often involve symptom management and disease-modifying drugs that may work for some patients but not for others. This is because neurological diseases exhibit a high degree of individual variability.

***Address for Correspondence**: Peluso Polidura, Department of Neurology, University of Turku, Turku University Hospital, 20520 Turku, Finland; E-mail: polidurapeluse@era.fi*

What works for one patient may not work for another, and side effects can be unpredictable. Personalized medicine, by contrast, seeks to understand the underlying genetic, molecular, and environmental factors contributing to each patient's disease, allowing for more precise and effective interventions. One of the key elements of personalized medicine is genetic profiling. Many neurological disorders have a genetic component, with specific mutations or genetic variations influencing disease risk and progression. In Parkinson's disease, researchers have identified several genes associated with an increased risk of developing the condition, such as the SNCA, LRRK2, and PARK7 genes. By conducting genetic testing, doctors can identify individuals at higher genetic risk, allowing for early interventions and tailored treatment plans [3].

The ability to identify genetic risk factors early in the disease process can significantly improve the management of neurological disorders. With a clear understanding of the genetic makeup of an individual, healthcare providers can design a treatment plan that is optimized for the patient's specific needs, reducing the risk of adverse side effects and improving treatment outcomes. Another critical aspect of personalized medicine in neurology is the use of biomarkers to monitor disease progression and treatment response. A biomarker is a measurable indicator of a biological process or condition, such as a protein, gene, or metabolic product that reflects disease activity. In multiple sclerosis, biomarkers such as Neurofilament Light chain (NFL) and Myelin Basic Protein (MBP) can be used to assess the degree of neurodegeneration and track disease progression. These biomarkers can also help evaluate the effectiveness of Disease-Modifying Therapies (DMTs). In Alzheimer's disease, biomarkers like amyloid-beta and tau proteins can be detected in Cerebrospinal Fluid (CSF) or through advanced neuroimaging techniques such as Positron Emission Tomography (PET) scans. The presence of amyloid plaques and tau tangles is a hallmark of Alzheimer's and can help diagnose the condition earlier than clinical symptoms would typically allow [4].

Pharmacogenomics is another key component of personalized medicine that plays a pivotal role in treating neurological disorders. This field involves studying how a person's genetic makeup affects their response to medications. For instance, certain genetic variations can influence how an individual metabolizes drugs, affecting their efficacy and safety. Some patients with Parkinson's disease may respond better to levodopa treatment, while others may experience side effects or develop drug resistance more quickly. Understanding the genetic factors that affect drug metabolism can help tailor treatment regimens to minimize side effects and improve therapeutic outcomes. In epilepsy, some patients may have genetic mutations that make them more prone to adverse reactions from certain anti-seizure medications. Pharmacogenomic testing can help identify the most effective AED for each individual, reducing the risk of treatment failure. By leveraging pharmacogenomic data, personalized medicine can optimize drug prescriptions, leading to more effective treatments with fewer adverse effects [5].

Conclusion

Personalized medicine is revolutionizing the way we approach the treatment of complex neurological disorders. By leveraging genetic information, biomarkers, and pharmacogenomics, healthcare providers can tailor treatment plans to the specific needs of individual patients. This approach promises to improve the effectiveness of treatments, minimize side effects, and enhance patient outcomes. However, challenges such as the complexity of neurological diseases, the cost of personalized interventions, and ethical considerations

must be addressed to fully realize the potential of personalized medicine. As research continues to uncover the genetic and molecular mechanisms underlying neurological diseases, the role of personalized medicine will only grow more important. With ongoing advancements in technology and a deeper understanding of the human genome, the future of treating complex neurological disorders looks promising. Personalized medicine holds the potential to transform the landscape of neurology, offering hope for patients with conditions that were once considered intractable or untreatable. The integration of personalized medicine into clinical practice is poised to bring about a new era of precision, providing better outcomes and improving the quality of life for individuals living with neurological disorders.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Wolfers, Thomas, Dorothea L. Floris, Richard Dinga and Daan van Rooij, et al. "From pattern classification to stratification: Towards conceptualizing the heterogeneity of Autism Spectrum Disorder." *Neurosci Biobehav Rev* 104 (2019): 240-254.

2. Poldrack, Russell A., Chris I. Baker, Joke Durnez and Krzysztof J. Gorgolewski, et al. "Scanning the horizon: Towards transparent and reproducible neuroimaging research." *Nat Rev Neurosci* 18 (2017): 115-126.

3. Rudin, Cynthia. "Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead." *Nat Mach Intell* 1 (2019): 206-215.

4. Topol, Eric J. "High-performance medicine: The convergence of human and artificial intelligence." *Nat Med* 25 (2019): 44-56.

5. Chartsias, Agisilaos, Thomas Joyce, Mario Valerio Giuffrida and Sotirios A. Tsaftaris. "Multimodal MR synthesis *via* modality-invariant latent representation." *IEEE Trans Med Imaging* 37 (2017): 803-814.